FDA panel: BioMarin muscle wastage drug data not persuasive

Nov 24 (Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration on Tuesday indicated that efficacy data submitted by BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle wastage disorder was not persuasive.